BlueCrest Capital Management’s Abiomed Inc ABMD Stock Holding History

BlueCrest Capital Management’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-27,737	Closed	-$8.07M	–	1938
2018 Q1	$8.07M	Buy	+27,737	New	+$7.03M	0.25%	71
2017 Q3	–	Sell	-5,134	Closed	-$736K	–	1145
2017 Q2	$736K	Buy	5,134 +2,833	+123%	+$381K	0.03%	519
2017 Q1	$288K	Buy	+2,301	New	+$267K	0.01%	538
2016 Q3	–	Sell	-8,533	Closed	-$933K	–	1040
2016 Q2	$933K	Buy	+8,533	New	+$849K	0.04%	375

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlueCrest Capital Management's ABMD Position: Q2 2018 in Review

BlueCrest Capital Management sold out of Abiomed Inc (ABMD) in Q2 2018, closing a stake of 27,737 shares — an estimated $8.07M sold.

BlueCrest Capital Management first reported a position in ABMD in Q2 2016 and held it in 4 quarters. The position peaked at $8.07M in Q1 2018. 527 funds tracked by Wall St. Rank hold ABMD as of Q2 2018.

BlueCrest Capital Management reported no remaining Abiomed Inc position as of Q2 2018 after selling out during the quarter.
BlueCrest Capital Management sold 27,737 Abiomed Inc shares in Q2 2018, an estimated $8.07M.
BlueCrest Capital Management first reported a position in Abiomed Inc in Q2 2016 and held it in 4 quarters.
BlueCrest Capital Management's Abiomed Inc position peaked at $8.07M in Q1 2018.
527 funds tracked by Wall St. Rank held Abiomed Inc as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.